New Oxford spinout Oxsed will lead commercialisation of rapid, cost-effective COVID-19 test.
Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19
Welcome to the Oxford University Innovation Q1 2020 update. OUI is now a month into its status as a virtual company with the entire office working from home, but we remain very much open for business. Below you’ll find all the usual updates from OUI and news from our spinouts, as well as an update on how Oxford is responding to the ongoing crisis.
Oxford University has adopted revised guidance to accelerate the licensing of relevant intellectual property (IP) for the duration of the COVID-19 pandemic, to avoid unnecessary delays or missed opportunities to understand, manage and protect against the threat posed.
‘Novel approach to cancer metabolism’ the target of Rising Tide Foundation partnership with Oxford University
The University will form a spinout company to take pioneering oncology research forward.
Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders.
Leading angel networks in Oxford merge to catalyse early-stage tech investment in the Oxford Cluster.
Y Combinator startup Prolific announces $1.2M seed round with participation from Pioneer Fund and prominent Silicon Valley Angel investors.
New virtual reality medical training app LIFE uses HTC VIVE Focus Plus for training doctors and nurses to save lives.